Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1Phase 1 1

Status

Recruiting 4

Sponsor Class

NIH 3INDUSTRY 1

Study Type

Interventional 3Observational 1

Sponsor

Cancer Type

Lymphoid 4Head & Neck 1

Conditions

Lymphoma 111Precursor Cell Lymphoblastic Leukemia-Lymphoma 109Lymphoma, Non-Hodgkin 105Leukemia, Lymphocytic, Chronic, B-Cell 88Lymphoma, Large B-Cell, Diffuse 84Lymphoma, Follicular 68Hodgkin Disease 54Burkitt Lymphoma 52Multiple Myeloma 51Lymphoma, B-Cell 51Recurrence 46Lymphoma, Mantle-Cell 46Leukemia, Myeloid, Acute 44Leukemia 37Neoplasms 35Hematologic Neoplasms 32Myelodysplastic Syndromes 29Lymphoma, B-Cell, Marginal Zone 26Waldenstrom Macroglobulinemia 22Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 19Lymphoma, T-Cell 18Lymphoma, T-Cell, Peripheral 16Leukemia, Myelogenous, Chronic, BCR-ABL Positive 16Leukemia, B-Cell 16Lymphoma, Large-Cell, Anaplastic 15Sarcoma 13Leukemia, Biphenotypic, Acute 13Mycosis Fungoides 11Melanoma 10Lymphoma, T-Cell, Cutaneous 10

Interventions

pomalidomide 1Vincristine 1Rituximab 1Prednisone 1Nivolumab 1Etoposide 1Doxorubicin 1Cyclophosphamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Epstein-Barr Virus Infections × Lymphoid × 30 days × Clear all
NCT00032513 2026-06-01

Genetic Studies of Chronic Active Epstein-Barr Disease

National Institutes of Health Clinical Center (CC)

Recruiting
300 enrolled
Lymphoid

Herpes Simplex, Infectious Mononucleosis, Lymphoproliferative Disorders, Virus Diseases, Epstein-Barr Virus Infections

NCT05389423 2026-06-01

Pomalidomide and Dose-Adjusted EPOCH +/- Rituximab for HIV-Associated Lymphomas

National Institutes of Health Clinical Center (CC)

Phase 1 Recruiting
25 enrolled
Lymphoid

Plasmablastic Lymphoma, Burkitt Lymphoma, Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Epstein-Barr Virus Infections

NCT03258567 2026-05-22

Nivolumab in Epstein-Barr Virus (EBV)-Positive Lymphoproliferative Disorders and EBV-Positive Non-HodgkinLymphomas

National Institutes of Health Clinical Center (CC)

Phase 2 Recruiting
40 enrolled
Lymphoid

Lymphoma, Lymphoproliferative Disorders, Epstein-Barr Virus Infections

NCT03394365 2026-05-22

ALLELE

Pierre Fabre Medicament

Phase 3 Recruiting
115 enrolled
Lymphoid

Lymphoproliferative Disorders, Epstein-Barr Virus Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡